Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.

@article{Koshy2013ImprovedSA,
  title={Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.},
  author={Matthew Koshy and Stacey A. Fedewa and Renu Malik and Mark K. Ferguson and Wickii Thambiah Vigneswaran and Lawrence Eric Feldman and Andrew William Howard and Khaled Abdelhady and Ralph R. Weichselbaum and Katherine S. Virgo},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2013},
  volume={8 7},
  pages={915-22}
}
INTRODUCTION Optimal management of clinical stage IIIA-N2 non-small-cell lung cancer (NSCLC) is controversial. This study examines whether neoadjuvant chemoradiation plus surgery improves survival rates when compared with other recommended treatment strategies. METHODS Adult patients from the National Cancer Database, with clinical stage IIIA-N2 disease… CONTINUE READING